• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care
    Get the next $CRTD alert in real time by email
    • Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.
    • Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.

    • Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations.

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurturing technology-enabled subsidiaries with scalable infrastructure and long-term value creation potential while maintaining Fly Flyte's operational independence and strategic focus. Creatd welcomes VTAK as a partner in Flyte's continued growth and success.

    "Creatd is committed to building a portfolio of operating companies in the small-cap space," said Jeremy Frommer, CEO of Creatd, Inc. "We see an opportunity to address the white space created by the contraction of middle markets over the last two decades. By integrating capabilities from banking, investing, advisory, branding, investor relations, financial analysis, and operational leverage, we can build a foundation of interlinked services to support growth-driven companies and provide pathways for them to scale or transition to listed entities."

    Fly Flyte is operational today, providing AI-enabled regional aviation services designed to increase accessibility and convenience. The company leverages certified aircraft, established routes, and scalable infrastructure to deliver real-time revenue while positioning for long-term expansion.

    About Creatd:

    Creatd, Inc. (OTCQB:CRTD) acquires and grows technology-driven companies in aviation, media, and advisory services. Through its shared services model, Creatd enables its portfolio companies to scale efficiently, improve margins, and expand market reach. For more information, visit www.creatd.com.

    Contact:

    [email protected]

    Forward-Looking Statements:

    This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business and our expectations with respect to the completion of the offering, the satisfaction of customary closing conditions related to the offering and the additional closings, the anticipated use of proceeds therefrom, and other statements that are predictive in nature. These statements can be identified often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "intends," "plans," "believes" and "projects," and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Such factors and risks include, among others, market and other risks, that the additional closings after today may not occur if certain closing conditions are not met, and that there can be no assurance that the Company will successfully uplist to a national securities exchange. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release contains forward-looking statements and is qualified in its entirety by, and should be read together with, the cautionary statements, risk factors and other disclosures contained in the Company's filings with the SEC and OTC Markets.



    Primary Logo

    Get the next $CRTD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRTD
    $VTAK

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $CRTD
    $VTAK
    SEC Filings

    View All

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    2/12/26 4:15:59 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    2/6/26 5:25:30 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    11/21/25 4:15:57 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $CRTD
    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 19.98% Strategic Stake in AI-Enabled Aviation Company Fly Flyte, Inc.

    Immediate Exposure to Revenue-Generating, Asset-Backed Regional Air Mobility Business Positioned Ahead of Anticipated Future Industry-wide eVTOL Commercialization Strategic Investment Expands Capital Allocation into High-Growth Infrastructure with Scalable Fleet Expansion and Long-Term Equity Upside Fort Mill, S.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) today announced a strategic minority investment in Fly Flyte, Inc. ("Flyte"), an FAA-certified regional aviation operator utilizing AI-enabled operations and a growing fleet of Cirrus Vision Jets. Flyte conducts its flight operations through its wholly owned subsidiary, Ponderosa Air, LLC (FAA Air Carrie

    2/17/26 7:45:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. Secures up to $36.5 Million in Strategic Institutional Financing to Accelerate Growth

    VTAK has Agreed to Terminate its At-The-Market ("ATM") Equity Offering Program Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation FORT MILL, S.C., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("Catheter Precision" or the "Company"), a leader in advanced electrophysiology solutions, today announced that it has agreed to the termination of its at-the-market ("ATM") equity offering program and has completed a strategic financing transaction with institutional investors for up to $36.5 million to support accelerated growth. Key Highlights: ATM equity program to be terminated. No future equity lines of credit or forward-

    2/12/26 7:15:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $CRTD
    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    1/20/26 4:20:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Director Caruso James Joseph converted options into 41 shares, increasing direct ownership by 456% to 50 units (SEC Form 4)

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    12/8/25 4:54:19 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Chairman of the Board and CEO Jenkins David A converted options into 43,006 shares, increasing direct ownership by 695% to 13,799 units (SEC Form 4)

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    12/8/25 4:45:07 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $CRTD
    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    1/7/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    1/22/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Creatd Appoints John Tabacco to Advise the Company on its Investigation into Naked Shorts and Advance its Blockchain Strategy

    John is recognized as one of the predominant experts in the operational frameworks of today's public financial markets.As part of the Company's internal task force, which includes experts in multiple fields, John will be one of the leaders advising on the Company's blockchain strategy as it battles illegal naked short selling and other abusive trading practices.NEW YORK, March 3, 2023 /PRNewswire/ -- Creatd, Inc. (OTCQB:CRTD, Upstream: CRTD))) ("Creatd" or the "Company"), a creator-first technology company, is pleased to announce the addition of John Tabacco, former President of tZERO Technologies, a blockchain-based digital security ecosystem launched by Overstock.com, Inc. Given the Compan

    3/3/23 11:55:00 AM ET
    $CRTD
    Publishing
    Consumer Discretionary

    $CRTD
    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $CRTD
    $VTAK
    Financials

    Live finance-specific insights

    View All

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Creatd to File Quarterly Financials on Friday, November 14; Schedules Investor Conference Call for Monday, November 17 at 4:30 PM ET

    NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) ("the Company" or "Creatd") today announced that it expects to file its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2025, on Friday, November 14, 2025. The Company will host an investor conference call on Monday, November 17, 2025, at 4:30 PM Eastern Time. The webinar can be accessed at the following link: https://creatd.zoom.us/webinar/register/WN_VOcC4tzpTmqOtoyiz70ThQ#/registration For the third quarter of 2025, Creatd estimates preliminary revenues of nearly $1,000,000, representing a 163% year-over-year increase to the third quarter of 2024. Revenues for the nine months ended September

    11/10/25 2:55:46 PM ET
    $CRTD
    Publishing
    Consumer Discretionary

    Creatd Launches Flyte Escapes: AI-Enhanced Luxury Travel Experiences for the Modern Era

    Creatd, Inc. (OTCQB:CRTD) introduces Flyte Escapes, a new luxury travel vertical that curates private jet journeys, five-star accommodations, and insider access, all seamlessly orchestrated with the assistance of Flyte's AI-powered systems.Designed for B2B partnerships, Flyte Escapes expands Creatd's footprint into the experience travel market, positioning the company for future collaborations, acquisitions, and new revenue streams. NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) today announced the official launch of Flyte Escapes, an AI-enhanced luxury travel vertical offering fully integrated private jet itineraries, curated stays, and exclusive access. Developed

    10/29/25 9:30:00 AM ET
    $CRTD
    Publishing
    Consumer Discretionary